1. Home
  2. DLNG vs MOLN Comparison

DLNG vs MOLN Comparison

Compare DLNG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.87

Market Cap

139.0M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.23

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DLNG
MOLN
Founded
2013
2004
Country
Greece
Switzerland
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
164.2M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
DLNG
MOLN
Price
$3.87
$4.23
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
54.7K
4.3K
Earning Date
03-05-2026
03-05-2026
Dividend Yield
5.14%
N/A
EPS Growth
30.14
N/A
EPS
1.29
N/A
Revenue
$158,275,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.37
$999.99
P/E Ratio
$3.02
N/A
Revenue Growth
4.34
N/A
52 Week Low
$3.18
$3.36
52 Week High
$5.35
$5.81

Technical Indicators

Market Signals
Indicator
DLNG
MOLN
Relative Strength Index (RSI) 60.55 48.40
Support Level $3.70 $4.11
Resistance Level $4.18 $4.28
Average True Range (ATR) 0.13 0.15
MACD 0.01 -0.01
Stochastic Oscillator 50.00 28.21

Price Performance

Historical Comparison
DLNG
MOLN

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: